Literature DB >> 18573140

Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells.

James A Hutchinson1, Dave Roelen, Paloma Riquelme, Beate G Brem-Exner, Oliver Witzke, Thomas Philipp, Martina Matthäi, Felix Gövert, Frans H J Claas, Eckhard Westphal, Ulrich Kunzendorf, Edward K Geissler, Fred Fändrich.   

Abstract

This report describes the case of patient FR, a 31-year-old recipient of a living-related kidney transplant from a donor against whom he was presensitized. Seventeen days prior to transplantation, a central venous infusion of transplant acceptance-inducing cells (TAICs) was administered to the patient. During the 27-month follow up, the patient experienced no acute rejection episodes under an immunosuppressive regime comprising anti-thymocyte globulin (ATG) induction, corticosteroids and tacrolimus. In a similar manner to the kidney transplant recipients treated preoperatively with TAICs in a previous study, patient FR achieved a state of donor-specific hypo-responsiveness. Most remarkably, the deliberate preoperative exposure of a sensitized patient to the sensitizing alloantigen did not heighten his response; on the contrary, after TAIC treatment and transplantation, HLA-specific antibodies were no longer detectable. The case of patient FR provides further evidence of the safety of pre-transplantation treatment with TAICs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573140     DOI: 10.1111/j.1432-2277.2008.00712.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  10 in total

Review 1.  Tolerance in clinical transplantation: progress, challenge or just a dream?

Authors:  Fred Fändrich
Journal:  Langenbecks Arch Surg       Date:  2011-03-17       Impact factor: 3.445

Review 2.  The exciting "bench to bedside" journey of cell therapies for acute kidney injury and renal transplantation.

Authors:  Sergio Dellepiane; Davide Medica; Alessandro Domenico Quercia; Vincenzo Cantaluppi
Journal:  J Nephrol       Date:  2017-03-21       Impact factor: 3.902

Review 3.  Regulatory myeloid cells in transplantation.

Authors:  Brian R Rosborough; Dàlia Raïch-Regué; Heth R Turnquist; Angus W Thomson
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

Review 4.  Regulatory dendritic cells for promotion of liver transplant operational tolerance: Rationale for a clinical trial and accompanying mechanistic studies.

Authors:  Angus W Thomson; Abhinav Humar; Fadi G Lakkis; Diana M Metes
Journal:  Hum Immunol       Date:  2017-10-31       Impact factor: 2.850

Review 5.  Macrophages in Transplantation: A Matter of Plasticity, Polarization, and Diversity.

Authors:  Sarah E Panzer
Journal:  Transplantation       Date:  2022-02-01       Impact factor: 5.385

6.  In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies.

Authors:  Christiane Broichhausen; Paloma Riquelme; Norbert Ahrens; Anja K Wege; Gudrun E Koehl; Hans J Schlitt; Bernhard Banas; Fred Fändrich; Edward K Geissler; James A Hutchinson
Journal:  Mol Ther Methods Clin Dev       Date:  2014-07-16       Impact factor: 6.698

Review 7.  Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms.

Authors:  Joseph R Scalea; Yusuke Tomita; Christopher R Lindholm; William Burlingham
Journal:  Front Immunol       Date:  2016-03-07       Impact factor: 7.561

Review 8.  Prospects of the Use of Cell Therapy to Induce Immune Tolerance.

Authors:  Zhenkun Wang; Xiaolong Liu; Fenglin Cao; Joseph A Bellanti; Jin Zhou; Song Guo Zheng
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

9.  Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs.

Authors:  Paloma Riquelme; Edward K Geissler; James A Hutchinson
Journal:  Transplant Res       Date:  2012-09-28

Review 10.  Tolerising cellular therapies: what is their promise for autoimmune disease?

Authors:  Chijioke H Mosanya; John D Isaacs
Journal:  Ann Rheum Dis       Date:  2018-11-02       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.